Lisa Allamassey

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial

Toby M. Maher, Ellen M. van der Aar, Olivier Van de Steen et al. · The Lancet Respiratory Medicine · 2018 · 235 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +7

Conversion from Calcineurin Inhibitor– to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial

Klemens Budde, Rohini Prashar, Hermann Haller et al. · Journal of the American Society of Nephrology · 2021 · 99 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +17

GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)

Jane C. Davies, Olivier Van de Steen, Silke van Koningsbruggen‐Rietschel et al. · Journal of Cystic Fibrosis · 2019 · 28 citations · Full text

Medicine, Molecular Medicine, Pharmacology +9

Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes: <i>In Vitro</i> and Phase 1 Studies

Julie Desrivot, Tim Van Kaem, Lisa Allamassey et al. · Clinical Pharmacology in Drug Development · 2021 · 10 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16